436
Participants
Start Date
February 4, 2024
Primary Completion Date
June 28, 2026
Study Completion Date
August 28, 2029
Radiation
IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
TP or PF regimen depended on investigator's choice.
A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
PD-1 inhibitor
Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
RECRUITING
Cancer hospital, CAMS, Beijing
Peking University Cancer Hospital & Institute
OTHER
Beijing Cancer Prevention & Treatment Society
OTHER
Hebei Medical University Fourth Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
Anyang Tumor Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Tengzhou Central People's Hospital
OTHER_GOV
The First Affiliated Hospital of Xiamen University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Second Affiliated Hospital of Xi'an Jiaotong University
OTHER
Affiliated Hospital of North Sichuan Medical College
OTHER
Changzhou Cancer Hospital of Soochow University
OTHER
Henan Cancer Hospital
OTHER_GOV
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER